Could this Heallthcare Stock really climb 1,370.59% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Holding NVDA? Read This NOW]( NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. [Learn more here.]( --------------------------------------------------------------- February 26, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Best way to buy gold today (not what you'd think)]( so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion. [Full details here.]( --------------------------------------------------------------- [American Tower Corporation]( Symbol: [AMT]( Recent Price: $189.93 Average Analyst Price Target: $237.40 (24.99%) Market Cap: $88.54B Last Year's EPS: $1.02 Consensus EPS Forecast: $1.13 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Brendan Lynch, analyst at Barclays, reiterates coverage on [American Tower Corporation (AMT)]( in the Real Estate sector with a Buy rating and a price target of $224 (1 month ago). [TipRanks.com]( also reports that [American Tower Corporation]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $237.40 . The target pricing ranges from a high forecast of $245 down to a low forecast of $224. [American Tower Corporation (AMT)](’s last closing price was $189.93 which would put the average price target at 24.99% upside. Here are 3rd party ratings for [AMT](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 40% (100 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Digital Dollar: Convenience or Control?]( the truth behind the digital dollar. Is it a step towards financial innovation or a leap into surveillance and control? See how you can protect yourself and your money with our free guide. [Protect Your Money ASAP]( --------------------------------------------------------------- [Cardlytics, Inc.]( Symbol: [CDLX]( Recent Price: $6.95 Average Analyst Price Target: $9.38 (34.89%) Market Cap: $272.82M Last Year's EPS: $-0.24 Consensus EPS Forecast: $0.00333 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Kreyer, analyst at Craig-Hallum, reiterates coverage on [Cardlytics, Inc. (CDLX)]( in the Communication Services sector with a Hold rating and a price target of n/a (3 days ago). [TipRanks.com]( also reports that [Cardlytics, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $9.38 . The target pricing ranges from a high forecast of $9 down to a low forecast of $12. [Cardlytics, Inc. (CDLX)](’s last closing price was $6.95 which would put the average price target at 34.89% upside. Here are 3rd party ratings for [CDLX](: - TipRanks.com: Hold - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- [Esperion Therapeutics, Inc.]( Symbol: [ESPR]( Recent Price: $2.61 Average Analyst Price Target: $10.30 (294.64%) Market Cap: $444.79M Last Year's EPS: $-0.46 Consensus EPS Forecast: $-0.42 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Zemansky, analyst at Bank of America Securities, reiterates coverage on [Esperion Therapeutics, Inc. (ESPR)]( in the Healthcare sector with a Hold rating and a price target of $2.5 (1 month ago). [TipRanks.com]( also reports that [Esperion Therapeutics, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.30 . The target pricing ranges from a high forecast of $9 down to a low forecast of $10. [Esperion Therapeutics, Inc. (ESPR)](’s last closing price was $2.61 which would put the average price target at 294.64% upside. Here are 3rd party ratings for [ESPR](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 39% (99 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Billionaires Race to Invest in AI Energy Breakthrough]( Jeff Bezos and Bill Gates are investing in AI energy. This AI-created energy is being hailed as the most exciting human discovery since fire. [Here’s how to invest alongside them.]( --------------------------------------------------------------- [Avidity Biosciences, Inc.]( Symbol: [RNA]( Recent Price: $14.04 Average Analyst Price Target: $36.00 (156.41%) Market Cap: $1.04B Last Year's EPS: $-0.66 Consensus EPS Forecast: $-0.76 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Yanan Zhu, analyst at Wells Fargo, reiterates coverage on [Avidity Biosciences, Inc. (RNA)]( in the Healthcare sector with a Buy rating and a price target of $50 (1 month ago). [TipRanks.com]( also reports that [Avidity Biosciences, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.00 . The target pricing ranges from a high forecast of $50 down to a low forecast of $23. [Avidity Biosciences, Inc. (RNA)](’s last closing price was $14.04 which would put the average price target at 156.41% upside. Here are 3rd party ratings for [RNA](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 32% (80 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Gamida Cell Ltd.]( Symbol: [GMDA]( Recent Price: $0.34 Average Analyst Price Target: $5.00 (1,370.59%) Market Cap: $44.85M Last Year's EPS: $-0.31 Consensus EPS Forecast: $-0.15 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Butler, analyst at JMP Securities, reiterates coverage on [Gamida Cell Ltd. (GMDA)]( in the Healthcare sector with a Hold rating (3 weeks ago). [TipRanks.com]( also reports that [Gamida Cell Ltd.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $7 down to a low forecast of $2. [Gamida Cell Ltd. (GMDA)](’s last closing price was $0.34 which would put the average price target at 1,370.59% upside. Here are 3rd party ratings for [GMDA](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 32% (80 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The next Covid pump is coming?]( Covid stimulus happened, some of the elites were perfectly positioned for big investing gains. Their wealth went up significantly, while many others were left scrambling for enough money to pay for their lifestyle. And I think this is going to happen again. But this time, the bubble is on a schedule. If you can make the right moves by January 31st, you may be able to harness a massive tailwind in your favor. Position yourself like it’s Covid all over again, but this time… You know what to buy, what to avoid, and how to never be left behind by the ultra-wealthy again. [It’s all in this free video.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoversAlert.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.[If you are not a human, click here.](By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software